Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Alnylam Pharmaceuticals (Nasdaq: ALNY) announces virtual presentations at two upcoming conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is scheduled for November 9, 2020, at 12:30 pm ET, followed by the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:00 pm ET. Investors can access a live audio webcast of each presentation on Alnylam's website, with replays available within 48 hours post-event. Alnylam is a leader in RNA interference therapeutics, focused on innovative medicines for rare genetic and other severe diseases.
- None.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
- 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020 at 12:30 pm ET
- Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 2:00 pm ET
A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI® (givosiran), approved in the U.S, EU, and Brazil. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
